
The use of circulating tumor DNA in patients with advanced colorectal cancer may provide early insight into who is and is not responding to treatment, according to an expert from Weill Cornell Medicine.

Your AI-Trained Oncology Knowledge Connection!


The use of circulating tumor DNA in patients with advanced colorectal cancer may provide early insight into who is and is not responding to treatment, according to an expert from Weill Cornell Medicine.

The novel search tool uses artificial intelligence to restructure trial information, making it easier for patients and providers to access clinical trial information.